You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameStreptokinase
Accession NumberDB00086  (BIOD00028, BTD00028)
TypeBiotech
GroupsApproved
Description

Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

Protein structureDb00086
Protein chemical formulaC2100H3278N566O669S4
Protein average weight47286.7 Da
Sequences
>Streptokinase Sequence DB00086
MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDIS
LKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSN
DDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQ
AKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGY
TIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKY
YVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAK
LLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEER
EVYSYLRYTGTPIPDNPNDK
Download FASTA Format
Synonyms
Streptokinase C precursor
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Kabikinase - Pws 1500000units/vialpowder for solution1500000 unitintravenous; intracoronaryPharmacia & Upjohn Inc1995-12-312001-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Kabikinase - Pws 250000 Unit/vialpowder for solution250000 unitintravenous; intracoronaryPharmacia & Upjohn Inc1995-12-311999-08-12Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Kabikinase - Pws 750000units/vialpowder for solution750000 unitintravenous; intracoronaryPharmacia & Upjohn Inc1995-12-312001-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptasepowder for solution250000 unitintravenous; intracoronaryCsl Behring Canada Inc1994-12-312012-02-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptasepowder for solution1500000 unitintravenous; intracoronaryCsl Behring Canada Inc1994-12-312012-02-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptasepowder for solution750000 unitintravenous; intracoronaryCsl Behring Canada Inc1994-12-312012-02-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptase Inj 1500000 Unit/vialpowder for solution1500000 unitintravenousHoechst Canada Inc.1991-12-311996-08-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptase Inj 250000unit/vialpowder for solution250000 unitintravenousHoechst Canada Inc.1981-12-311996-08-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Streptase Inj 750000unit/vialpowder for solution750000 unitintravenousHoechst Canada Inc.1981-12-311996-08-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII8X1OXL3SNU
CAS number9002-01-1
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
PharmacodynamicsStreptokinase creates an active complex which promotes the cleavage of the Arg/Val bond in plasminogen to form the proteolytic enzyme plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism of actionPlasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Powder for solutionintravenous; intracoronary1500000 unit
Powder for solutionintravenous; intracoronary250000 unit
Powder for solutionintravenous; intracoronary750000 unit
Powder for solutionintravenous1500000 unit
Powder for solutionintravenous250000 unit
Powder for solutionintravenous750000 unit
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
hydrophobicity-0.728Not Available
isoelectric point5.12Not Available
References
Synthesis Reference

Lawrence Isaac Galler, “Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy.” U.S. Patent US6087332, issued July, 1997.

US6087332
General ReferencesNot Available
External Links
ATC CodesB01AD01
AHFS Codes
  • 20:12.20
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Streptokinase.
AcenocoumarolStreptokinase may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Streptokinase.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Streptokinase.
AnagrelideAnagrelide may increase the anticoagulant activities of Streptokinase.
ApixabanStreptokinase may increase the anticoagulant activities of Apixaban.
AprotininThe therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.
ArgatrobanStreptokinase may increase the anticoagulant activities of Argatroban.
Bismuth SubsalicylateThe risk or severity of adverse effects can be increased when Bismuth Subsalicylate is combined with Streptokinase.
BivalirudinStreptokinase may increase the anticoagulant activities of Bivalirudin.
CaffeineCaffeine may increase the anticoagulant activities of Streptokinase.
CangrelorCangrelor may increase the anticoagulant activities of Streptokinase.
CilostazolCilostazol may increase the anticoagulant activities of Streptokinase.
CitalopramCitalopram may increase the anticoagulant activities of Streptokinase.
ClopidogrelClopidogrel may increase the anticoagulant activities of Streptokinase.
Dabigatran etexilateStreptokinase may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinStreptokinase may increase the anticoagulant activities of Dalteparin.
DanaparoidStreptokinase may increase the anticoagulant activities of Danaparoid.
DesirudinStreptokinase may increase the anticoagulant activities of Desirudin.
DesvenlafaxineDesvenlafaxine may increase the anticoagulant activities of Streptokinase.
DiclofenacDiclofenac may increase the anticoagulant activities of Streptokinase.
DiflunisalDiflunisal may increase the anticoagulant activities of Streptokinase.
DihydrocodeineDihydrocodeine may increase the anticoagulant activities of Streptokinase.
DipyridamoleDipyridamole may increase the anticoagulant activities of Streptokinase.
DuloxetineDuloxetine may increase the anticoagulant activities of Streptokinase.
EdoxabanStreptokinase may increase the anticoagulant activities of Edoxaban.
EnoxaparinStreptokinase may increase the anticoagulant activities of Enoxaparin.
EpoprostenolThe risk or severity of adverse effects can be increased when Streptokinase is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Streptokinase.
EscitalopramEscitalopram may increase the anticoagulant activities of Streptokinase.
EtodolacEtodolac may increase the anticoagulant activities of Streptokinase.
FenoprofenFenoprofen may increase the anticoagulant activities of Streptokinase.
FloctafenineFloctafenine may increase the anticoagulant activities of Streptokinase.
FluoxetineFluoxetine may increase the anticoagulant activities of Streptokinase.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Streptokinase.
FluvoxamineFluvoxamine may increase the anticoagulant activities of Streptokinase.
Fondaparinux sodiumStreptokinase may increase the anticoagulant activities of Fondaparinux sodium.
HeparinStreptokinase may increase the anticoagulant activities of Heparin.
IbuprofenIbuprofen may increase the anticoagulant activities of Streptokinase.
IloprostThe risk or severity of adverse effects can be increased when Streptokinase is combined with Iloprost.
IndomethacinIndomethacin may increase the anticoagulant activities of Streptokinase.
KetoprofenKetoprofen may increase the anticoagulant activities of Streptokinase.
KetorolacKetorolac may increase the anticoagulant activities of Streptokinase.
LevomilnacipranLevomilnacipran may increase the anticoagulant activities of Streptokinase.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Streptokinase.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Streptokinase.
MeloxicamMeloxicam may increase the anticoagulant activities of Streptokinase.
MilnacipranMilnacipran may increase the anticoagulant activities of Streptokinase.
NabumetoneNabumetone may increase the anticoagulant activities of Streptokinase.
NadroparinStreptokinase may increase the anticoagulant activities of Nadroparin.
NaproxenNaproxen may increase the anticoagulant activities of Streptokinase.
OxaprozinOxaprozin may increase the anticoagulant activities of Streptokinase.
ParoxetineParoxetine may increase the anticoagulant activities of Streptokinase.
PiroxicamPiroxicam may increase the anticoagulant activities of Streptokinase.
PrasugrelPrasugrel may increase the anticoagulant activities of Streptokinase.
RivaroxabanStreptokinase may increase the anticoagulant activities of Rivaroxaban.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Streptokinase.
SertralineSertraline may increase the anticoagulant activities of Streptokinase.
SulindacSulindac may increase the anticoagulant activities of Streptokinase.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Streptokinase.
TicagrelorTicagrelor may increase the anticoagulant activities of Streptokinase.
TiclopidineTiclopidine may increase the anticoagulant activities of Streptokinase.
TinzaparinStreptokinase may increase the anticoagulant activities of Tinzaparin.
TirofibanTirofiban may increase the anticoagulant activities of Streptokinase.
TolmetinTolmetin may increase the anticoagulant activities of Streptokinase.
TreprostinilThe risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.
VenlafaxineVenlafaxine may increase the anticoagulant activities of Streptokinase.
VilazodoneVilazodone may increase the anticoagulant activities of Streptokinase.
VorapaxarVorapaxar may increase the anticoagulant activities of Streptokinase.
VortioxetineVortioxetine may increase the anticoagulant activities of Streptokinase.
WarfarinStreptokinase may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

1. Plasminogen

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Plasminogen P00747 Details

References:

  1. Caballero AR, Lottenberg R, Johnston KH: Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis. Infect Immun. 1999 Dec;67(12):6478-86. Pubmed
  2. Alessi MC, Juhan-Vague I: [Thrombolytics and their use] Rev Prat. 1999 Oct 1;49(15):1654-8. Pubmed
  3. Chaudhary A, Vasudha S, Rajagopal K, Komath SS, Garg N, Yadav M, Mande SC, Sahni G: Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis. Protein Sci. 1999 Dec;8(12):2791-805. Pubmed
  4. Parry MA, Zhang XC, Bode I: Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci. 2000 Feb;25(2):53-9. Pubmed
  5. Korol’chuk VI, Makohonenko IeM, Sederkhol’m-Vil’iams SA: [Plasminogen binding with decapeptide and polypeptide fragments of streptokinase] Ukr Biokhim Zh. 1999 Sep-Oct;71(5):51-8. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Proteinase-activated receptor 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: cleavage

Components

Name UniProt ID Details
Proteinase-activated receptor 1 P25116 Details

References:

  1. McRedmond JP, Harriott P, Walker B, Fitzgerald DJ: Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000 Feb 15;95(4):1301-8. Pubmed

Enzymes

1. Cytosolic phospholipase A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytosolic phospholipase A2 P47712 Details

References:

  1. Kawaguchi H, Iizuka K, Sano H, Yasuda H: Effect of streptokinase on prostacyclin synthesis and phospholipase activity in cultured pulmonary artery endothelial cells. Biochim Biophys Acta. 1990 Dec 10;1055(3):223-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 13, 2013 10:49